european us drugs groups threatening dominate worlds market leaving japanese counterparts trailing according study datamonitor londonbased strategy consultants in particular european groups dominance driven innovative research development new products international marketing strength only three japanese companies takeda sankyo shionogi among worlds top 25 drugs groups none top 10 japan ran trade deficit pounds 800m 1989 repeated price cuts implemented ministry health welfare seriously handicapped japanese industry while drug prices us increased 40 per cent 1982 1988 japan fell 39 per cent in 1991 alone shionogi fujisawa suffered average price cuts 95 per cent 9 per cent respectively japanese groups hit disproportionately dependence domestic market takeda largest japanese group generates 986 per cent turnover japan japanese spending research development doubled past 10 years though sales increased 50 per cent the datamonitor report warns however japanese rd push may come late increasing penetration japanese market western drugs groups this argues likely accelerate consolidation japanese industry the japanese pharmaceutical market 19921995 datamonitor 106 baker street london w1m 1la 071 625 85 48 pounds 695